"Texas-based Taysha Gene Therapies announced last week that it had concluded a Series B round of financing worth $95 million. The round was led by Fidelity Management & Research Company, with additional investment from BlackRock, GV, Invus, Casdin Capital, Franklin Templeton, Octagon Capital, Perceptive Advisors LLC, Sands Capital, ArrowMark Partners and Venrock Healthcare Capital Partners."
You can read the full article here.